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Abstract
Double-strand break repair is executed by two major repair pathways: non-homologous end joining (NHEJ) and
homologous recombination (HR). Whereas NHEJ contributes to the repair of ionizing radiation (IR)-induced double strand
breaks (DSBs) throughout the cell cycle, HR acts predominantly during the S and G2 phases of the cell cycle. The rare-cutting
restriction endonuclease, I-SceI, is in common use to study the repair of site-specific chromosomal DSBs in vertebrate cells.
To facilitate analysis of I-SceI-induced DSB repair, we have developed a stably expressed I-SceI fusion protein that enables
precise temporal control of I-SceI activation, and correspondingly tight control of the timing of onset of site-specific
chromosome breakage. I-SceI-induced HR showed a strong, positive linear correlation with the percentage of cells in S
phase, and was negatively correlated with the G1 fraction. Acute depletion of BRCA1, a key regulator of HR, disrupted the
relationship between S phase fraction and I-SceI-induced HR, consistent with the hypothesis that BRCA1 regulates HR
during S phase.
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Introduction
Repair of mammalian chromosomal double-strand breaks
(DSBs) entails use of one of two major repair pathways: non-
homologous end-joining (NHEJ) and homologous recombination
(HR) (reviewed in [1,2,3,4]). These repair functions take place in
relation to other chromosome processes such as transcription and
DNA replication, and DNA replication alters the parameters
governing DSB repair in several ways. First, the process of DNA
replication itself is thought to be a major cause of endogenous
DSBs. Second, replication generates a second copy of the
chromosome in the form of a sister chromatid, which may favor
DSB repair by homologous recombination, (‘‘sister chromatid
recombination’’ – SCR) [5,6,7,8]. Third, cell cycle-dependent
variations in the activity of cyclin-dependent kinases affect the
likelihood of engaging the DSB processing enzymes required for
HR [9]. In budding yeast, where HR is the major DSB repair
pathway, repair of ionizing radiation (IR)-induced DSBs engages
SCR in preference to interhomolog recombination [7]. Similarly,
in mammalian cells, intrachromosomal HR (of which SCR is likely
a major component) is more efficient than interchromosomal HR
[10]. In contrast to the constraints on HR, NHEJ can, in principle,
operate at any stage of the cell cycle.
Studies in which IR was used to induce chromosome breakage
have supported the idea that HR and NHEJ contribute differently
to DSB repair at different stages of the cell cycle [11,12,13]. In the
chicken lymphoblastoid cell line, DT40, cells defective for the HR
gene RAD54 reveal increased IR-sensitivity specifically in S phase
[14]. In contrast, DT40 cells lacking the NHEJ gene KU70 are
hypersensitive to IR during G1 and early S phase, consistent with
a major role for NHEJ in repair of breaks generated prior to
replication. Similar cell cycle dependencies of IR sensitivity and
IR-induced HR were observed in mammalian cells, further
supporting the notion that IR-induced HR is limited to the S/
G2 cell cycle phases [12]. Indeed, in cells lacking the NHEJ factor
XRCC4, IR-induced DSBs generated in G1 triggered elevated
levels of HR in the subsequent S/G2. This suggests that the
mechanism engaged to repair a DSB is a function of the cell cycle
stage at which repair is executed, rather than the stage at which
the DSB itself is induced [11,13].
The rare-cutting restriction endonuclease, I-SceI, has become a
major tool for analyzing mechanisms of DSB repair [15]. I-SceI-
induced breaks are likely limited to the canonical I-SceI target site
and the DSB ends generated by I-SceI-mediated breakage are
defined by the enzyme’s known endonuclease activity. In contrast,
IR-induced DSBs are distributed across the genome and the DSB
ends may be chemically modified [16]. For these reasons, the
‘‘rules’’ governing I-SceI-induced DSB repair might differ from
those governing an IR-induced DSB. The ligand-binding domain
(LBD) of the estrogen receptor (ER) has been used to regulate the
activity of a variety of nuclear proteins, since fusion proteins
containing the ER LBD are retained in the cytoplasm until
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correct folding of the released fusion protein, thereby activating
the LBD-fused nuclear protein. The mouse ER LBD mutant
G525R exhibits a ,1000-fold reduction in 17ß-estradiol binding
affinity compared to the wildtype protein, but retains normal
affinity for the synthetic ER ligands and functional estrogen
antagonists, tamoxifen (TAM) and 4-hydroxy-tamoxifen (4OHT)
[20]. The corresponding human ER LBD mutant (G521R, termed
‘‘ER
T’’) has similar properties [17]. The 4OHT affinity of the
human ER LBD mutant ER
T2 (G400V/M543A/L544A) is
approximately 4-fold higher than that of ER
T [21]. Ectopic
DNA enzymes such as Cre, Flp and I-SceI have successfully been
controlled by fusion with ER
T [21,22,23], or with other nuclear
hormone receptors [24]. In work described here, we characterize a
set of I-SceI-ER
T or ER
T2 fusion proteins and define optimal
configurations for tight control of I-SceI activity, as measured by a
sensitive I-SceI-inducible HR reporter. By enriching cells in
specific phases of the cell cycle prior to activation of I-SceI, we




Expression plasmids for ER
T and ER
T2 were described
previously [21]. New constructs described here were generated
by standard cloning procedures. Control RNAi duplex against
luciferase (59-CGUACGCGGAAUACUUCGAdTdT-39) and
RNAi duplex against BRCA1 (59-AAUCACAGUGUCCUUUAU-
GUAdTdT-39) were purchased from Dharmacon.
Cell Lines and Cell Culture
U2OS SCR #18 cells were described previously [25]. ER
T
stable lines were maintained in phenol red-free DMEM supple-
mented with 10% charcoal-stripped fetal bovine serum (CS-FBS,
Atlanta Biologicals), 0.2 ng/mL EGF (Invitrogen) and 100 U
penicillin/100 mg streptomycin at 37uC and 6% CO2.T o
generate ER
T stable lines, the various ER
T expression constructs
were transfected into U2OS SCR #18 cells and 0.4 mg/mL G418
(Sigma-Aldrich) was added to the medium 2 days after
transfection. After 2 weeks under continuous selection, G418-
resistant colonies were isolated and screened by flow cytometry for
4OHT-induced HR.
Antibodies and Immunoblotting
Cells were lysed in NP-40 lysis buffer (50 mM Tris-HCl
[pH 8.0], 1% NP-40, 150 mM NaCl) supplemented with protease
inhibitor cocktail (Roche). Cell lysates were resolved by SDS-
PAGE on NuPAGEH Novex Bis-Tris Gels (Invitrogen) and
analyzed by blotting with mouse monoclonal anti-Myc (9E10)
antibody.
Immunofluorescence Staining
Cells on glass coverslips were treated with 1 mM 4OHT for the
desired length of time (0–180 min), fixed in 3% paraformalde-
hyde/2% sucrose, permeabilized in Triton X-100 solution (0.5%
Triton X-100, 20 mM HEPES [pH 7.4], 50 mM NaCl, 3 mM
MgCl2, 300 mM sucrose), stained with anti-Myc (9E10) followed
by goat anti-mouse IgG rhodamine-conjugated secondary anti-
body and imaged on a Zeiss microscope.
Recombination Assays
Cells were plated at a density of 0.4610
6 cells/well on 6-well
plates overnight prior to assay. Cells were treated with 1 mM
4OHT (Sigma-Aldrich) and GFP
+ frequencies were measured 24–
72 hr post-treatment by flow cytometry using an FC500 (Beckman
Coulter).
Cell Cycle Arrest
In order to arrest/synchronize cells at different stages of the cell
cycle, several drug treatments were used. For G2/M synchroni-
zation, cells were treated for 16 hrs in 0.4 ng/mL nocodazole
(Sigma-Aldrich), harvested by mitotic shake-off, and plated at a
concentration of 0.4610
6 cells/well on 6-well plates with or
without 1 mM 4OHT for 48 hrs. For G1 arrest by double drug
treatment, cells were treated for 16 hrs in 0.4 ng/mL nocodazole
(Sigma-Aldrich), harvested by mitotic shake-off, and plated at a
concentration of 0.4610
6 cells/well on 6-well plates in 40 mM
lovastatin (Axxora) for 48 hrs. 4OHT was added at a final
concentration of 1 mM to induce I-SceI at the same time as cells
were plated into lovastatin. For G1 arrest by single drug treatment,
40 mM lovastatin was added to cells with or without 1 mM 4OHT
for 48 hrs.
Cell Cycle Profiling
Cells were pulsed with 10 mM bromodeoxyuridine (BrdU,
Sigma-Aldrich) for 20 min, collected, and fixed with ice cold 70%
ethanol. For staining cells were treated with 2 M HCl/0.5%
Triton X-100, neutralized with 0.1 M Na2B4O7 (pH 8.5), stained
with mouse anti-BrdU primary antibody (Boehringer-Mannheim)
and then goat anti-mouse IgG FITC-conjugated antibody (Jackson
ImmunoResearch). Finally, cells were resuspended in 38 mM
sodium citrate/69 mM propidium iodide/100 mg/mL RNaseA
and propidium iodide/FITC staining levels were measured by
flow cytometry using an LSR II (BD Biosciences).
Southern Blotting
Genomic DNA was extracted from 5–10610
6 cells using the
ArchivePure Cell/Tissue Kit (5 PRIME). Southern blotting for
wtGFP was performed as described previously [25].
Transfection
0.5610
6 U2OS SCR NEIE were plated overnight then
transfected with 120 pmol siRNA using Lipofectamine
TM 2000
(Invitrogen). GFP
+ frequencies were measured 72 hr post-
transfection by flow cytometry using an LSR II (Beckman
Coulter).
Results
We used a previously described HR reporter containing two
tandem mutant copies of the gene encoding the enhanced green
fluorescent protein (EGFP, here termed GFP)( Figure 1A) [25,26].
The first GFP copy (Tr-GFP) is truncated at the 59 end and the
second GFP copy (I-SceI-GFP) is full length, but is interrupted by
the 18 base pair (bp) recognition site for the rare-cutting
endonuclease, I-SceI, rendering this copy nonfunctional. Expres-
sion of I-SceI induces a site-specific DSB within the reporter and
stimulates HR. Recombination between the two GFP copies by
either intra- or inter-chromatid HR (Figure 1A), but not single
strand annealing, can generate wild type GFP (wtGFP), which is
readily quantified by flow cytometry.
We fused cDNA sequences encoding ER mutants, ER
T or
ER
T2, in frame with the 39 end of I-SceI in the I-SceI expression
construct pcDNA3ß-myc-NLS-I-SceI, to generate ‘‘NIE’’ and
‘‘NIE2’’ constructs respectively (Figure 1B). We generated U2OS
HR reporter cell lines (U2OS #18 [25]) stably transfected with
either of these constructs and screened individual clones for the
Temporal Regulation of I-SceI-Induced HR
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Steady state levels of the fusion proteins are shown in Figure 1C.
4OHT-responsive clones were identified for each construct;
however, I-SceI-ER
T generated a higher proportion of responsive
clones than I-SceI-ER
T2. In clones that were found to be
functionally responsive, as measured by induction of GFP
+ events
by 4OHT, the addition of 4OHT also produced the expected
nuclear accumulation of myc-tagged I-SceI-ER
T or -ER
T2 fusion
protein. However, despite cultivation of the cells in phenol red-free
medium and charcoal-stripped serum, every responsive clone
revealed variable, weakly positive nuclear immunostaining for myc
during passage in the absence of 4OHT. Further, all NIE or NIE
2
4OHT-responsive clones revealed an accumulation of GFP
+
events in the absence of 4OHT at rates well above that observed
in the parental clones lacking I-SceI-ER
T or -ER
T2 expression
(Figure 1D and data not shown). This indicates that the NIE and
NIE
2 fusion proteins were not perfectly controlled and that I-SceI-
mediated breakage occurred even in the absence of the inducing
4OHT ligand.
It was reported previously that the addition of more than one
ER
T domain can improve the background of Cre fusion proteins
[18]. We therefore generated an I-SceI-ER
T fusion protein in
which a second ER
T domain was fused, in frame, between the
NLS and I-SceI sequences of NIE, to generate a construct
encoding a myc-NLS-ER
T-I-SceI-ER
T fusion protein (here
termed ‘‘NEIE’’ – Figure 1B). Following stable expression of
NEIE in U2OS HR reporter cell line #18 (Figure 1C), we
identified 4OHT-responsive clones and observed that, when
cultivated in phenol red-free medium and charcoal-stripped
serum, 4OHT-responsive NEIE clones appeared to exhibit
improved stability in the absence of 4OHT than either NIE or
NIE2 clones, while retaining equivalent responsiveness in the
presence of the ligand (Figure 1D). The majority of 4OHT-
responsive NEIE clones revealed a persistently low background
frequency of GFP
+ events, while none of the 4OHT-responsive
NIE or NIE2 clones showed this pattern. Representative clones of
each type are shown in Figure 1. While this work was in progress,
Bennardo et al. reported similar observations using an indepen-
dently generated system [23].
To further characterize the performance of the NEIE fusion
protein, we used immunostaining for myc followed by immuno-
fluorescence microscopy to study the subcellular distribution of
the NEIE fusion protein either in the absence of 4OHT or at
defined times following addition of 4OHT to the medium
(Figure 2A). Notably, in the absence of 4OHT, the NEIE fusion
protein was observed in the cytoplasm and was fully excluded
from the nucleus. Within 10 to 20 minutes of 4OHT addition,
the NEIE protein was found to accumulate in the nucleus, and by
1 hour nearly every cell contained fully nuclear-localized NEIE
protein.
Figure 1. Optimization of I-SceI-ER
T fusion proteins for controlled induction of chromosome breakage. A) Repair of an I-SceI-induced
DSB by intra- or interchromatid gene conversion. Double vertical lines: restriction site cut by I-SceI; Solid arrow: promoter sequence. B) I-SceI
expression constructs used in this study. Each construct has an N-terminal triple-Myc tag and nuclear localization signal. ER
T represents the G521R
mutant and ER
T2 represents the mutant containing the G400V/M543A/L544A triple mutation of the human estrogen receptor ligand-binding domain.
NI – NLS-I-SceI; NIE – NLS-I-SceI-ER
T; NIE2 – NLS-I-SceI-ER
T2; NEIE – NLS-ER
T-I-SceI-ER
T. C) Stable expression of I-SceI fusion proteins. Asterisk indicates
endogenous Myc protein and can be used as a loading control. Arrowheads indicate predicted sizes of I-SceI fusion proteins. D) 4OHT-induced HR in
NIE, NIE2, and NEIE cell lines. Error bars represent the standard error of the mean (S.E.M.) for triplicate samples.
doi:10.1371/journal.pone.0016501.g001
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was active, we sought evidence of chromosome breakage within
the HR reporter during the 4OHT response. We harvested
genomic DNA (gDNA) from clone NEIE-6.46 either before the
addition of 4OHT, or at defined time points following 4OHT
addition, and analyzed the structure of the HR reporter by
Southern blotting, as described in Materials and Methods. Briefly,
PstI-digested gDNA fragments that are probed with GFP reveal a
single fragment of ,5.9 kb if the reporter locus is intact. If the I-
SceI site has been cut, a lower molecular weight species of ,4.6 kb
is observed (Figure 2B). Only a very small fraction (,1%) of cells
at any given time point following 4OHT addition revealed the I-
SceI-cut ,4.6 kb band (Figure 2B). The I-SceI-cut fragment was
noted within 30 minutes following 4OHT addition and its
intensity was approximately constant over time (Figure 2B). This
suggests that the NEIE fusion protein is functionally active at the
time of nuclear entry. Further, the low but consistent level of I-
SceI-induced breakage observed at all time points following
4OHT addition suggests that there is a dynamic equilibrium
between I-SceI-mediated chromosome breakage and DSB repair,
with the balance tipped heavily in favor of repair in the cells
examined here. This might reflect efficient religation of the I-SceI-
induced DSB by precise NHEJ, which accurately reconstitutes the
I-SceI site, provided canonical NHEJ is intact [27,28]. However,
in other experiments in which we examined breakage at the I-SceI
site using Southern blotting in Ku70
2/2 or XRCC4
2/2 mouse
embryonic stem cells, we failed to observe dramatic increases in
steady state levels of I-SceI breakage, despite the loss of the
canonical NHEJ pathway (data not shown). This might reflect cell
type-specific effects or the engagement of alternative error-free
DSB repair pathways. Further, the activity of the I-SceI
endonuclease might be reduced in the context of the fusion
protein.
Importantly, removal of 4OHT from the culture medium of
induced NEIE cells did not disrupt the nuclear distribution of the
activated NEIE protein, and the strong nuclear myc signal
persisted for up to 12 hours (data not shown). Therefore, although
4OHT can be used to activate I-SceI with precise timing,
withdrawal of 4OHT appears not to immediately inactivate the
enzyme.
The above experiments were performed with 1 mM 4OHT
calculated to saturate LBD receptor occupancy. To confirm that
this dose was appropriate, we generated a dose-response curve for
two of the NEIE stable cell lines, NEIE-6.39 and NEIE-6.46
(Figure 2C). I-SceI-induced HR in each test sample was assayed
as the percentage of 4OHT-induced GFP
+ cells. The resultant
dose-response curves revealed median effective doses (ED50)o f
approximately 40 nM for each cell line - values similar to that
reported previously for a Cre-ER
T fusion protein [21]. 4OHT-
induced HR in each cell line showed a modest dependence on the
plating density of cells (Figure 2D).
To determine the temporal relationship between DSB induction
and HR, we examined the emergence of GFP
+ cells as a function
of duration of treatment of cell line NEIE-6.46 in 4OHT (1 mM).
Figure 2. Time course and dose dependence of HR induced by 4-hydroxytamoxifen in NEIE cells. A) Immunofluorescence detection of
4OHT-induced NEIE nuclear accumulation over time. NEIE-6.46 cells were treated with 4OHT for the indicated times (in minutes) before fixation and
staining. B) Southern blot detection of a 4OHT-induced site-specific DSB within the HR reporter. Arrowhead indicates the migration of PstI-restricted
gDNA that has been cut by I-SceI. The uncut band is not shown in this figure. C) The effect of 4OHT concentration on NEIE-induced HR. The average
raw percentage of GFP
+ cells within the culture is shown. D) The effect of cell density on NEIE-induced HR. Shown is the average percentage of GFP
+
cells, corrected for the background level of GFP
+ cells.
doi:10.1371/journal.pone.0016501.g002
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+ cells first became detectable by flow cytometry within 10 to
12 hours of 4OHT addition (Figure 3A). Thereafter, GFP
+ cells
accumulated in 4OHT-treated populations at a fixed rate
(Figure 3B). This rate of increase of the GFP
+ fraction was
remarkably constant at ,0.05% per hour (,1.2% per day), even
when cells were passaged in 4OHT for a period of up to one
month (Figure 3C). In contrast, cells passaged in the absence of
4OHT showed no increase in the GFP
+ fraction over this one-
month period, indicating that the NEIE cell line is tightly
regulated when cultivated in medium lacking estrogenic com-
pounds.
We asked whether I-SceI-induced HR is influenced by the cell
cycle stage during which I-SceI is activated. To study this, we used
combinations of lovastatin and nocodazole to synchronize cells at
various points in the cell cycle. Lovastatin inhibits HMG-CoA
reductase, causing cells to arrest in G1 [29], while nocodazole is an
antimitotic agent that disrupts microtubules and arrests the cell
cycle at the G2/M phase [30]. Importantly, these drugs are not
predicted to have a direct impact on DSB repair. Cell
synchronization methods are depicted Figure 4A. In all treatment
groups, cells were plated at the start of the experiment, were
exposed to 4OHT 48 hours later, and were harvested for analysis
of HR (measured by induction of GFP
+ cells) and cell cycle
distribution at the 96 hour time-point (i.e., 48 hours after initial
exposure to 4OHT). Note that cells were exposed to 4OHT
continuously throughout the second 48 hour period. Upon this
framework we imposed one or more of the following two
treatments: first, Nocodazole treatment for 16 hours, followed by
release from nocodazole by mitotic shake-off, washing and
replating, with the replating timed to coincide with the addition
of 4OHT (the 48 hour time point). Second, lovastatin treatment,
added to the medium at the same time as 4OHT (i.e., the 48 hour
time point) and left in the medium until the time of harvesting
(96 hour time point). Four treatment groups were analyzed: one
received control diluents (‘‘vehicle’’) but no cell cycle synchroniz-
ing drug; a second received nocodazole synchronization only; a
third received lovastatin only; and a fourth received nocodazo-
le+lovastatin (Figure 4A). As expected, lovastatin or nocozazole
alone each diminished the percentage of cells in S phase at the end
point of the experiment, and this effect was enhanced if the two
drug treatments were combined (Supplemental Table S1).
To determine whether cell cycle status at the time of harvest
(i.e., the 96 hour time point) had any predictive value for the
efficiency of HR measured at that same time point, we plotted the
percentage of I-SceI-induced GFP
+ cells against the percentage of
cells in G1, S or G2 phases of the cell cycle, combining data from
the four different treatment groups into one graph (Figure 4B).
We generated regression lines for each of two independent clones
(NEIE-6.39 and NEIE-6.46) and calculated the optimal fit of
regression lines for each combination by the least squares method
(Figure 4B). This analysis revealed a strong positive linear
correlation (R
2=0.90 and 0.85 for NEIE-6.39 and NEIE-6.46,
respectively) between the percentage of cells in S phase and the
level of 4OHT-induced HR (Figure 4B). We also observed a
weak negative correlation (R
2=0.62 and 0.52) between the
percentage of cells in G1 and the efficiency of 4OHT-induced
HR. These results show that I-SceI-induced HR in this system is
strongly correlated with S phase, and that HR is inefficient in G1.
This suggests that I-SceI induces a cell cycle-dependent pattern of
HR equivalent to that deduced from previous analysis of IR-
induced DSB repair [11,12,14]. However, some caution is needed
in interpreting our results. First, the nature of the cell cycle
synchronization is not absolute; it is to be expected that cell cycle
distribution will vary over the 48 hours of 4OHT treatment, as cell
cultures encounter the G1 block imposed by lovastatin or traverse
G1 and enter S, in the case of the release from nocodazole.
Second, we cannot exclude the possibilty that I-SceI-mediated
DSB induction is itself cell cycle regulated. With these caveats in
mind, the data does appear to support the notion that,
Figure 3. I-SceI activation induces a fixed rate of HR and GFP
+
cell accumulation. A) Initial emergence of GFP
+ cells in NEIE-6.46 cells
occurs after 10 hrs in 4OHT. B) The frequency of GFP
+ cells increases in a
linear fashion over the normal time course of experiments in this study
(72 hrs). C) Linear increase in the frequency of GFP
+ cells continues in
cells exposed to 4OHT for up to 28 days. Open circle: no 4OHT. Black
triangles: with addition of 4OHT.
doi:10.1371/journal.pone.0016501.g003
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phase.
BRCA1 is known to interact with Rad51 in discrete nuclear foci
during the S and G2 phases of the cell cycle [31] and to relocalize
rapidly to sites of replication arrest in S phase cells treated with
HU [32]. In addition, BRCA mutant embryos contain chromo-
somes with ‘‘chromatid-type’’ structural aberrations, which are
considered to arise from replication across a damaged template
and from recombination errors in S phase [33,34]. These
observations led to the proposal that BRCA1 regulates SCR
during S phase [35]. To test this hypothesis, we transfected U2OS
HR NEIE cells with control siRNA or siRNA directed against
human BRCA1, and plated cells directly into 4OHT 24 hours
post-transfection, harvesting cells 48 hours later (Figure 4A and
4C). Depletion of BRCA1 reduced 4OHT-induced HR in U2OS
HR NEIE cells, in comparison to control siRNA, but with
minimal disruption of the cell cycle profile (Figure 4B). These
results suggest that loss of BRCA1 disrupts the relationship
between of S phase fraction and HR, and therefore support the
long-standing hypothesis that BRCA1 has a major influence on
HR during S phase.
Discussion
The development and characterization of a system to control I-
SceI expression in a tight temporal fashion is an important
Figure 4. BRCA1 depletion disrupts HR in S phase. A) Cell synchronization methods. B) U2OS HR NEIE-6.39 and 6.46 cell lines were used to
determine the cell cycle profile and frequency of HR after 48 hrs of 4OHT exposure in cultures synchronized at different stages of the cell cycle. Black
circles represent data from several experiments involving different drug treatment protocols, as described in Materials and Methods. These
treatments include vehicle only, Lovastatin (Lov) alone, and cells treated with Nocodazole (Noc) and released into either vehicle or Lovastatin. A
strong positive correlation is noted between the percentage of cells in S phase and the efficiency of HR, as indicated by the line of best fit (NEIE-6.39
y=0.0244x+0.5395, R
2=0.89503; NEIE-6.46 y=0.0456x+0.3533, R
2=0.85193). A negative correlation between the percentage of cells in G1 phase and
the efficiency of HR is also noted (NEIE-6.39 y=20.0357x+3.1208, R
2=0.61909; NEIE-6.46 y=20.0555x+4.588, R
2=0.52032). The U2OS HR NEIE-6.46
cell line was transfected with control siRNA (siLuc – siLuciferase) or BRCA1 siRNA (siBRCA1). 24 hrs post-transfection cells were replated in either 1 mM
4OHT or vehicle control, for a further 48 hours. Green squares indicate siLuc data points and red triangles indicate BRCA1 siRNA data points. C)
Immunoblotting for BRCA1 in different siRNA treated groups.
doi:10.1371/journal.pone.0016501.g004
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include the study of cell cycle relationships, as discussed above, to
potential use in chromatin immunoprecipitation studies [36], real-
time imaging, high-throughput screening and tight control of I-
SceI activity in animal models. The accurate interpretation of
siRNA experiments might also benefit from a tractable inducible
DSB system such as that described here, where DSB induction
could be initiated when siRNA knockdown is at its peak. The use
of a recombination reporter is a stringent test of the activity of the
enzyme – probably more so than attempts to directly measure
breakage at the locus. Notably, cultivation of cells in the presence
of phenol red and endogenous estrogens in serum that was not
charcoal stripped, triggered the gradual accumulation of GFP
+
products of I-SceI-induced HR in the absence of 4OHT (data not
shown). This suggests that, if residual estrogens are present in the
culture medium, they can produce some basal activation of the
fusion protein, even in its optimal ‘‘EIE’’ configuration. This
suggests that the application of this technology in animal models
may require additional levels of control.
In this report, we have identified an optimal configuration of
ER-LBD-I-SceI fusion protein that provides tight control of I-SceI
activity in the absence of activating ligand. Our experience
matches closely that described for ER LBD control of the Cre
recombinase [18] and the results of Bennardo et al. in control of I-
SceI [23]. In each, the addition of ER LBD domains to both the
N- and C-termini of the enzyme provide optimal control with
retention of enzymatic activity. This result is also consistent with
the crystal structure of I-SceI, in which the active site is predicted
to be unaffected by modification of either the N- or C-termini of
the polypeptide [37].
We used this construct, stably expressed in U2OS HR reporter
cells, to study the relationship between cell cycle stage and HR, by
activating the I-SceI enzyme in cell cultures enriched at different
cell cycle stages. By comparing the percentage of cells in a given
cell cycle stage at the time of I-SceI activation against the HR
outcome, we observed a strong positive correlation between the
percentage of cells in S phase and the percentage of measured
GFP
+ HR events. As noted above, these experiments do not
distinguish between S phase restriction of I-SceI-mediated
breakage and S phase restriction of the HR pathway. However,
given the known properties of I-SceI and precedent in the
literature [11,13], it is perhaps more likely that it is the
engagement of HR itself that exhibits the observed cell cycle
restriction. It will be valuable to re-examine this question in other
cell types that can be synchronized in other ways. Indeed, the
availability of this tightly regulated form of I-SceI will provide new
opportunities to study interactions between the cell cycle, cell
differentiation and mammalian DSB repair.
In view of the strong S phase linkage of I-SceI-induced HR in
this system, treatments that strongly perturb HR without
significantly affecting cell cycle distribution of the culture will
likely affect HR during S phase. One such treatment, acute
siRNA-mediated depletion of BRCA1, produced exactly these
results, supporting the long-standing hypothesis that BRCA1
executes a major HR function during S phase [38].
Supporting Information
Table S1 Cell Cycle data and I-SceI-induced HR values
for data shown in Figure 4B.
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